2019
DOI: 10.1016/j.yjmcc.2019.08.003
|View full text |Cite
|
Sign up to set email alerts
|

EZH2 as a novel therapeutic target for atrial fibrosis and atrial fibrillation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
58
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 52 publications
(61 citation statements)
references
References 45 publications
2
58
1
Order By: Relevance
“…These biological processes are important processes involved in the pathophysiological mechanism of AF. Recent research showed that there is a positive correlation between fibrosis and AF, and down-regulation of EZH2 could inhibit Ang-II-induced atrial enlargement and fibrosis and reduce AF vulnerability [ 16 ]. Reactome pathway analysis revealed that the DEGs were associated with the extracellular matrix (ECM) organization and collagen formation.…”
Section: Discussionmentioning
confidence: 99%
“…These biological processes are important processes involved in the pathophysiological mechanism of AF. Recent research showed that there is a positive correlation between fibrosis and AF, and down-regulation of EZH2 could inhibit Ang-II-induced atrial enlargement and fibrosis and reduce AF vulnerability [ 16 ]. Reactome pathway analysis revealed that the DEGs were associated with the extracellular matrix (ECM) organization and collagen formation.…”
Section: Discussionmentioning
confidence: 99%
“…The method of isolating primary mice atrial fibroblasts is mainly for Song et al, 2019) and was performed as previously described.…”
Section: Methodsmentioning
confidence: 99%
“…At the end of the 16‐week HFD feeding, in vivo cardiac dimensions and functional parameters were assessed by ultrasound instrument (Vivid 7, GE Healthcare). Echocardiography was performed under continuous anesthesia with 2% isoflurane inhalation as previously described (Song et al, 2019). Cardiac parameters included an examination of left atrial diameter (LAD), heart rate (HR), and left ventricle ejection fraction (LVEF).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Increasing evidence demonstrates that anomalous profiles of histone modifications contribute to the development of diseases such as AF. For instance, patients suffering from AF have increased expression of EZH2, encoding the histone methyltransferase responsible for the H3K27me3 signature, in both atrial cardiomyocytes and fibroblasts [116] . An additional wellknown example applies to histone deacetylases (HDACs) that act as proteostasis regulators in AF, by removing acetyl groups from the lysine residues of nucleosomal histone tails and various non-histone proteins.…”
Section: Histone Modificationsmentioning
confidence: 99%